INS and prostate carcinoma: In case of IR in prostate cancer patients, heterogeneous binding of insulin was inhibited on the platelet surface and that is why the level of insulin was found to be low and here DCN-2 might impart the major role in the reduction or impairment of insulin action in the condition as described before [21].